In A549 cells, PF-3644022 pretreatment effectively prevented SRC-3 phosphorylation at S857 following TNF-α or anisomycin stimulation. In senescent AG07719A cells, PF-3644022 slightly reduced IL-6 levels at 1.0 µM and 2.5 µM but had no effect at 5 µM. In IL‐33-stimulated BMMCs, inhibitor pretreatment inhibited TNF, IL‐6, IL‐13 and GM‐CSF production compared with the stimulated condition without inhibitor. In a separate A549 experiment, PF-3644022 significantly decreased TNF-α-induced IL-6 promoter-dependent luciferase activity compared with DMSO. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced stimulus-induced SRC-3 phosphorylation in lung cells
Cell-based study · A549 cells [1]
A549 cells were pretreated with PF-3644022 before stimulation with TNF-α or anisomycin, with DMSO as control. PF-3644022 effectively prevented phosphorylation of SRC-3 at S857.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 2.5, 5, 10 μM
- Exposure duration
- for 30 min followed by stimulation with either 10 ng/ml TNF-α (C) or 10 μg/ml anisomycin (D) for 30 min
- Method
- pretreated
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: TNF-α 10 ng/ml. Compound effect isolated by the comparison: DMSO or 1, 2.5, 5, 10 μM of PF-3644022.
Methods and source locations
Compound reported in the paper: PF-3644022
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Phosphorylation of SRC-3 at S857 is dependent on MK2 (S54); Figure 4 legend (S248, S249)
level of phosphorylation of SRC-3 at S857: level of phosphorylation of SRC-3 at S857; comparator: DMSO — Results > Phosphorylation of SRC-3 at S857 is dependent on MK2 (S54); Figure 4 legend (S249)
IL-6 levels in inhibitor-treated senescent cells
Cell-based study · AG07719A cells [2]
For AG07719A cells, PF-3644022 had no effect on IL-6 levels when used at 5 µM, but reduced IL-6 levels slightly when used at 1.0 and 2.5 µM. The data refer to inhibitor-treated senescent cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.0 µM, 2.5 µM and 5 µM
- Exposure duration
- the inhibitors being present throughout the experiment and replaced at each medium change
- Method
- the culture medium was supplemented with the inhibitor dissolved in DMSO
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: PF-3644022
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Conditioned medium collection and SASP assay (S18, S20); Results > Suppression of the SASP using p38 inhibitors (S47); Results > Suppression of the SASP using MK2 inhibitors (S55); Fig. 3 legend (S72)
IL-6 levels (normalised to the cell number and expressed as pg/ml medium per 30,000 cells): IL-6 levels (normalised to the cell number and expressed as pg/ml medium per 30,000 cells); comparator: an equivalent volume of the solvent DMSO was added to the medium at a final concentration of 0.1 % (v/v) — Results > Suppression of the SASP using p38 inhibitors (S47); Results > Suppression of the SASP using MK2 inhibitors (S55); Fig. 3 legend (S72)
Inhibition of cytokine production in stimulated BMMCs
Cell-based study · BMMCs [3]
BMMCs were pretreated with the inhibitor at 5 μm before IL‐33 stimulation. Compared with the stimulated condition without inhibitor, treatment inhibited production of TNF, IL‐6, IL‐13 and GM‐CSF.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μm
- Exposure duration
- for 1 h as shown and then either left unstimulated or stimulated with 10 ng mL−1 IL‐33 for 8 h
- Method
- pretreated
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: IL‐33 10 ng mL−1. Compound effect isolated by the comparison: no inhibitor, IL‐33 stimulated condition.
Methods and source locations
Compound reported in the paper: PF-3644022
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > IL‐33‐induced cytokine production requires the p38‐activated kinases MK2 and MK3 (S32); Methods > Cell culture (S117); Figure 2 legend (S178, S180, S181, S183)
TNF, IL‐6, IL‐13 and GM‐CSF secreted into the media: TNF, IL‐6, IL‐13 and GM‐CSF secreted into the media; comparator: no inhibitor, IL‐33 stimulated condition — Results > IL‐33‐induced cytokine production requires the p38‐activated kinases MK2 and MK3 (S32); Figure 2 legend (S181)
Reduced TNF-α-induced promoter-dependent luciferase activity in A549 cells
Cell-based study · A549 cells [1]
A549 cells received PF-3644022 pretreatment at 10 μM, with DMSO as control. TNF-α-induced IL-6 promoter-dependent luciferase activity decreased significantly with treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- after 48 h treated for 30 min
- Method
- pretreatment
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: TNF-α; pGL3-IL-6-promoter vector 120 ng. Compound effect isolated by the comparison: either the MK2 inhibitor PF-3644022, or DMSO as control.
Methods and source locations
Compound reported in the paper: PF-3644022
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > SRC-3 is required for MK2-mediated induction of IL-6 mRNA expression in response to TNF-α (S101, S102, S103); Figure 8 legend (S310)
IL-6 promoter-dependent luciferase: IL-6 promoter-dependent luciferase; comparator: 0.2 μl DMSO — Results > SRC-3 is required for MK2-mediated induction of IL-6 mRNA expression in response to TNF-α (S101, S103)